Skip to main content
. 2019 Sep 27;121(9):751–757. doi: 10.1038/s41416-019-0581-8

Fig. 3.

Fig. 3

Progression-free survival (PFS) and overall survival (OS) in patients with and without high-risk (t(4;14) and/or del(17p) cytogenetics (a, d)). PFS and OS in patients with and without gain of 1q21 (b, e). PFS and OS in patients with high-risk (t(4;14) and/or del(17p) cytogenetics, with gain of 1q21 alone or neither one (c, f))